Platinum-based chemotherapy for variant castrate-resistant prostate cancer. - Wikidata - wikimedia - TriplyDB

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

http://www.wikidata.org/entity/Q36977870

about

DNA damage response and prostate cancer: defects, regulation and therapeutic implications The many faces of neuroendocrine differentiation in prostate cancer progression Targeting the adaptive molecular landscape of castration-resistant prostate cancer Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Chemotherapy options in castration-resistant prostate cancer METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.Aggressive variants of castration-resistant prostate cancer Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.Nanoways to overcome docetaxel resistance in prostate cancer.Molecular pathways and targets in prostate cancer Resistance emerges to second-generation antiandrogens in prostate cancer.The role of epithelial plasticity in prostate cancer dissemination and treatment resistance Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.Small cell carcinoma of the prostate.Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Chemotherapy in Prostate Cancer.A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.FOXA1 inhibits prostate cancer neuroendocrine differentiation.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

P2860

Q26829155-51709D99-93C9-49BD-B6A4-41F972A97602 Q26992049-C0802448-C8D7-4476-9F80-A6D6958E1112 Q27022821-152B6E95-B641-4A51-A319-D055689CA8C0 Q28075965-BA3212C8-12BF-463C-97DA-58DA9464C4D5 Q28078477-D4EFC2B5-6E81-4C93-8DCB-591EF684C67E Q31108842-58A263F6-65B3-4E7D-B5E8-47CDEF0D73E2 Q33414629-458621E9-4370-47F1-B3C6-384B4AEA1700 Q33429467-29A75739-1EA0-4BDB-97AE-8AFCA00D54FC Q33584594-B8F44FCC-EC0C-4BB5-B519-E08734C96287 Q33621410-77D18F17-BF33-4AE3-A9F7-AEE292D77257 Q33693256-17A2157F-4269-46F1-8D4F-1DF3748579A4 Q33701534-B9B02067-95EA-42F4-B05A-6645E16D13ED Q33909084-EE1FF493-7B6C-449E-92D1-E862BCF63370 Q34365632-6DE8700C-AEBA-4CCB-A288-F71A96294DF6 Q34369873-4CFD859E-E6CA-4D2B-BFEB-2E3443104F57 Q34505037-C5ECAE87-0FDB-4656-B6B8-07AE34E37692 Q35551492-EA0AA51E-19FC-448E-AEAE-0BF793BA2B68 Q35861427-EE5483E4-DA60-4E5F-AD0D-E36FDF72E4F3 Q36082118-B798A518-70B3-4A02-AA1D-35F81537340B Q36436763-0876F77C-8494-44E9-A33E-B6F061BA840A Q36765820-C69B055E-20E5-4C2E-8DD3-EF6020E7FC39 Q36776738-907F1B5D-ACB1-475F-9732-F70A6981464A Q36862668-26B9D15A-2612-4E96-83B3-E63EDC3F7A24 Q37221588-839D0996-F9CD-47B6-8DA8-9162A3AA47B0 Q37417870-FF147475-F3A6-4A84-86E6-72CAB1528D06 Q38188869-D6FC5F3F-6621-4354-9C23-F0B2DFE85704 Q38192816-E2447883-F1AB-4007-A6F9-D2A1850C14A4 Q38209356-7CEC0C21-89A4-4F32-82A1-2582D49D1F7A Q38232184-E4AD7A04-3062-4459-8B95-085468CBF2B6 Q38362686-60F5A75D-B936-4469-83CA-B7101AA4E6E7 Q38374417-BD597435-3F3A-4763-96A3-260693220551 Q38555599-4AE7A65B-859D-4C77-BD99-81BCCE43B6E3 Q38720538-65735B3A-36E9-4EA2-835B-1E613C0E5374 Q38865758-B065F673-EE41-4E1A-9C79-DEFA84374172 Q38893882-74A81525-C213-4375-ABBF-FCCBEAE98973 Q38930155-E4F33B20-19BA-40A6-B980-80017B6E791A Q38982680-9DC7A785-5135-465C-9202-C2FE310A8CD6 Q39016544-DCCACCB0-0509-4170-B21C-78C0CF6B743E Q39044979-B057A8E1-4989-4A46-86C5-B0F59D47AD0C Q39051337-3D515E2A-92D4-40BA-835A-9FAF600B27A8

P2860

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

http://www.wikidata.org/entity/Q36977870

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

@en

type

label

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

@en

prefLabel

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

@en

P1433

Q36977870-54E818C6-3720-4D92-81EB-C25F3A4FC2FF

P1476

Q36977870-F3D9148D-3774-4E3D-874F-6D377F358120

P2093

Q36977870-038C8B10-BD6C-4D38-A5EF-8FE0250267DE

Q36977870-03DCFBF3-23B2-47BA-8A60-A7914F83EC5A

Q36977870-0B1AAE15-9D81-4D8B-A02D-958CC49A2647

Q36977870-0B5E4827-12EF-47B2-ABF6-694731110064

Q36977870-10847900-D731-4171-9B3B-5B467F2A3CF7

Q36977870-11DF2920-9155-4853-ADB1-E53E41652BAE

Q36977870-131B4B77-051F-4A36-9824-71B105904B17

Q36977870-143C0EBD-7C1F-4FF1-8914-A32015FE4EBF

Q36977870-3A8BCFCD-F878-423B-9252-DEF370041D05

Q36977870-4ACDF129-BB1F-4588-932B-688BD8548C97

P2860

Q36977870-0291E658-14B9-4948-B1A7-B5F49792EE33

Q36977870-17083314-ED79-4C4E-8DD3-0FBFE080244D

Q36977870-35BEBAC8-24DD-4227-80B3-EBBE010739B1

Q36977870-37F88354-480B-4A00-A8DD-AD5383E0E0D7

Q36977870-3E1E4B8A-267D-4C18-B998-0C655A6D02E9

Q36977870-43D17F4C-B8FC-4C2E-B0A4-4D91B709D651

Q36977870-4A32348E-5BEF-4AB2-91BF-D0582692282C

Q36977870-4F88D168-F435-486C-8759-AD6C21DA67E0

Q36977870-56EF6D58-350F-4221-9D88-D899DF8333DF

Q36977870-58EFA846-0D3E-46AA-84AF-D140FF805AA2

P304

Q36977870-FEAF6CB4-827E-411B-ACEF-FA420180E1F2

P31

Q36977870-A1102B4C-3250-4B66-A50C-966EAF324909

P356

Q36977870-5C6A4561-CB0C-4A63-BC49-E428A9A330E7

P407

Q36977870-533C3C55-62D6-4083-82C4-CECC7D9F4E08

P433

Q36977870-B7F05F37-E1D4-4D60-8903-71C62FFABAE6

P478

Q36977870-6D054C5D-1A85-40B6-A0D9-23C96A6CDC70

P577

Q36977870-9ACB1E4B-0C43-45A9-A52A-5C1D28266B83

P698

Q36977870-DB7F791B-3C87-474A-B1CE-0128E4D9A6D8

P921

Q36977870-EAF0FF05-0C7A-4484-912A-BE2C95D783BD

P932

Q36977870-5AA06FF1-9736-48C0-803A-8546FEC1DDBA

P356

1078-0432.CCR-12-3791

P1433

Clinical Cancer Research

P1476

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

@en

P2093

Amado J Zurita

http://www.w3.org/2001/XMLSchema#string

Ana M Aparicio

http://www.w3.org/2001/XMLSchema#string

Andrea L Harzstark

http://www.w3.org/2001/XMLSchema#string

Charles Ryan

http://www.w3.org/2001/XMLSchema#string

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Jeri Kim

http://www.w3.org/2001/XMLSchema#string

John C Araujo

http://www.w3.org/2001/XMLSchema#string

Lance C Pagliaro

http://www.w3.org/2001/XMLSchema#string

Nizar M Tannir

http://www.w3.org/2001/XMLSchema#string

Patricia Troncoso

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells.

Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy.

P304

3621-3630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-3791

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23649003

http://www.w3.org/2001/XMLSchema#string

P921

P932

3699964

http://www.w3.org/2001/XMLSchema#string